acute bronchiolitis is defined as an acute viral lower respiratory tract infection affecting children under the age of two, characterized clinically by a one- to three-day history of coryzal symptoms (common cold) that progresses to a persistent cough, tachypnea (rapid breathing), chest recessions, and diffuse wheezing or crackles on auscultation. It is a clinical diagnosis where the inflammation and mucus buildup within the smallest airways (bronchioles) lead to increased respiratory effort and frequent feeding difficulties, with the illness typically peaking between days three and five before gradual resolution. Is this definition of acute bronchiolitis okay?
Reading File
Searching PubMed
acute bronchiolitis definition diagnosis children
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Searching the Web
acute bronchiolitis definition clinical diagnosis AAP NICE guidelines 2024 coryzal prodrome peak day 3-5
I now have excellent material from NICE guidelines, AAP, Canadian Paediatric Society, and multiple textbooks. Here is my full assessment:
Assessment of Your Acute Bronchiolitis Definition
Your definition is clinically accurate and well-structured. It maps closely to the NICE guideline (NG9, updated 2025), the American Academy of Pediatrics (AAP) clinical practice guideline, the Canadian Paediatric Society (CPS) statement, and multiple textbook sources. Below is a point-by-point breakdown.
What You Got Right
1. Age criterion ("under 2 years")
Correct and consistent across all major guidelines and textbooks. NICE specifies "babies and children under 2 years of age, most commonly in the first year of life, peaking between 3 and 6 months." The AAP and CPS use the same under-2 cutoff. Swanson's Family Medicine Review and Cummings Otolaryngology both confirm this.
2. Viral etiology / lower respiratory tract
Correct. Both NICE and the CPS define it as "a viral lower respiratory tract infection." The AAP adds that it involves "acute inflammation, edema, and necrosis of epithelial cells lining small airways, and increased mucus production" - which your mention of "inflammation and mucus buildup" captures well.
3. Coryzal prodrome of 1-3 days
This is taken almost verbatim from NICE NG9 (1.1.3): "a coryzal prodrome lasting 1 to 3 days." The CPS describes it as "a two-to-three-day viral prodrome." Your phrasing is accurate.
4. Progressive symptoms: cough, tachypnea, chest recessions, wheeze/crackles
Exactly matches NICE's diagnostic criteria (1.1.3), which requires persistent cough PLUS tachypnoea or chest recession (or both), AND wheeze or crackles on auscultation (or both). The AAP similarly lists "rhinorrhea, cough, tachypnea, wheezing, rales, and increased respiratory effort." Your wording is aligned.
5. Clinical diagnosis
Correct. All major guidelines explicitly state bronchiolitis is a clinical diagnosis based on history and physical examination. Laboratory tests and imaging are generally not indicated.
6. Peak at days 3-5
Confirmed directly by NICE NG9 (1.1.2): "symptoms usually peak between 3 and 5 days." Your definition reflects this accurately.
7. Feeding difficulties
Correct. NICE flags "poor feeding (typically after 3 to 5 days of illness)" as a common associated feature. The AAP and CPS both note feeding difficulty as a key feature driving hospitalization decisions.
Minor Points Worth Noting
a) "Diffuse wheezing or crackles" - slight nuance
Your definition says "diffuse wheezing or crackles." In practice, both can be present simultaneously (not exclusively one or the other), and NICE says "wheeze or crackles (or both)." The CPS similarly notes "wheeze, crackles." Saying "diffuse" is acceptable but keep in mind crackles in bronchiolitis tend to be fine and widespread; if crackles are persistently focal, NICE recommends considering pneumonia instead.
b) Illness course / resolution
You say it peaks at days 3-5 "before gradual resolution." NICE adds a useful specific: cough resolves in 90% of infants within 3 weeks. You could optionally include this to make the definition more complete for clinical counselling purposes.
c) Apnoea in young infants
This is a feature your definition omits, but it is a significant one flagged by NICE (1.1.5): infants under 6 weeks may present with apnoea without other classic signs. For a brief definition this omission is reasonable, but worth knowing.
d) "Typical illness" framing
Your definition doesn't specify the exclusion criteria (e.g., this is a first episode, recurrent wheeze raises suspicion for viral-induced wheeze or early asthma - NICE 1.1.7). For a clinical teaching definition, this is not required, but it is worth being aware of.
Summary
| Element | Your Definition | Guideline/Textbook Consensus |
|---|---|---|
| Age < 2 years | Yes | Yes (NICE, AAP, CPS) |
| Viral lower respiratory tract | Yes | Yes |
| 1-3 day coryzal prodrome | Yes | Yes (NICE NG9 exactly) |
| Persistent cough | Yes | Yes |
| Tachypnea | Yes | Yes |
| Chest recessions | Yes | Yes |
| Wheeze / crackles | Yes | Yes |
| Clinical diagnosis | Yes | Yes |
| Peak days 3-5 | Yes | Yes (NICE) |
| Feeding difficulties | Yes | Yes (NICE, CPS) |
| Apnoea in young infants | Not mentioned | NICE flags this |
| Resolution timeline | Partial | 90% cough-free by 3 weeks (NICE) |
Your definition is accurate and can be used confidently. The only meaningful addition you might consider for completeness is noting that cough typically resolves within 3 weeks, and that apnoea can be the sole presentation in infants under 6 weeks.
Sources: NICE NG9 Bronchiolitis guideline, CPS Bronchiolitis statement, AAP Clinical Practice Guideline, Swanson's Family Medicine Review, p. 583, Cummings Otolaryngology, p. 3804.
So its not too long right for a definition
For a clinical definition, it's on the longer side - but not unreasonably so. Here's the honest take:
It's about right for a teaching/reference definition. It runs roughly 80 words and does the job of a definition that's meant to be used in a clinical context - it tells you the population, the cause, the typical presentation, the mechanism, and the time course all in one place. That's actually useful.
A textbook one-liner would just be: "Bronchiolitis is a viral lower respiratory tract infection affecting children under 2 years, characterised by inflammation and obstruction of the bronchioles, presenting with cough, tachypnoea, wheeze, and chest recession." - that's ~30 words.
Your version is longer because it includes:
- The coryzal prodrome duration (1-3 days) - this is a diagnostic criterion, worth keeping
- The peak timing (days 3-5) - clinically useful, not standard in most one-line definitions
- Feeding difficulties - a management consideration, not strictly part of the definition
Verdict: If this is for a clinical guide, exam notes, or teaching material, the length is justified and appropriate. If it's purely a dictionary-style definition, you could trim the peak timing and feeding difficulties. Nothing in it is wrong or padded - it's just a fuller definition rather than a minimal one.
Epideimology of acute bronchiolitis
Finding Sources
Searching PubMed
bronchiolitis epidemiology incidence hospitalization infants
Searching the Web
acute bronchiolitis epidemiology global incidence RSV seasonality risk factors 2023 2024
Finding Sources
Reading Article
Reading File
Reading Web Page
bronchiolitis epidemiology incidence prevalence hospitalization risk factors seasonality
I now have solid epidemiological data from multiple sources. Here is the full breakdown:
Epidemiology of Acute Bronchiolitis
1. Incidence and Prevalence
- Bronchiolitis affects more than one-third of all children in the first two years of life, making it one of the most common illnesses of early childhood (CPS).
- It is the most common lower respiratory tract infection in young children globally (AAFP, 2023).
- It is the most common cause of hospitalisation in the first year of life.
- Over the past 30 years, hospitalisation rates have risen from 1% to 3% of all infants annually (CPS). In the US, 2-3% of children under 12 months are hospitalised each year (Cummings Otolaryngology).
- A 2024 systematic review (Heemskerk et al., PMID 39098881) found primary care incidence rates ranging from 0.8 to 330 per 1,000 population (median 109), and emergency department rates of 7.5-144 per 1,000 (median 48), with the highest rates consistently in infants under 1 year.
2. Age Distribution
- Occurs in children under 2 years of age.
- Most common in the first year of life, with peak incidence at 3-6 months of age (NICE NG9).
- Nearly all children are infected with RSV (the main causative virus) by the age of 2 years (Swanson's Family Medicine Review).
- The illness is generally more severe in younger infants, particularly those under 3 months.
3. Sex
- Males are affected slightly more often than females and tend to have more severe disease - a finding consistently noted across multiple studies, though the mechanism is not fully established.
4. Causative Agents
- RSV (Respiratory Syncytial Virus) is responsible for the majority of cases and is by far the most common cause.
- Other viruses include:
- Human metapneumovirus (hMPV)
- Rhinovirus
- Parainfluenza virus
- Adenovirus
- Influenza virus
- Human bocavirus
- Coronavirus
- Co-infection with multiple viruses occurs in 10-30% of hospitalised young children (CPS).
- Importantly, primary RSV infection does not confer lasting protective immunity, so reinfection is common throughout life (though subsequent infections are milder).
5. Seasonality
- In temperate climates (Northern Europe, North America), bronchiolitis follows a clear winter seasonal pattern:
- RSV season typically runs from October/November through March/April.
- Peak activity usually occurs in December-January.
- In Canada, RSV season begins between November and January and persists for 4-5 months (CPS).
- Post-COVID-19 disruption: surveillance data show that RSV seasons shifted - with earlier onset and higher incidence rates in 2021-2024, particularly in children under 5, as a consequence of reduced immune exposure during pandemic lockdowns. Some regions saw incidence rates over four times pre-pandemic levels (Irish surveillance data, 2024).
- In tropical and subtropical regions, seasonality is less distinct and more linked to rainy seasons and humidity.
6. Risk Factors for Severe Disease
Host factors:
- Age under 3 months
- Prematurity (< 35 weeks gestation)
- Congenital heart disease (especially haemodynamically significant)
- Chronic lung disease / bronchopulmonary dysplasia
- Immunodeficiency
- Neuromuscular disorders impairing secretion clearance
- Low birth weight
Environmental / social factors:
- Overcrowding (households with >6 people)
- Attendance at daycare
- Exposure to siblings (increases viral transmission)
- Lack of breastfeeding (breastfeeding reduces severity by >70% and hospitalisation risk significantly - Red Book 2021)
- Secondhand smoke exposure / air pollution (2025 meta-analysis, PMID 40358039, confirms air pollution as independent hospitalisation risk factor)
- Low socioeconomic status / public insurance
Note: Birth month is a strong predictor in the US - infants born in summer (e.g., June) are twice as likely to be infected during their first RSV season compared to those born in October, as they are younger during the peak season (CDC/INSPIRE study, 2024).
7. Global Burden
- Bronchiolitis and RSV-related lower respiratory tract infection are among the leading causes of infant morbidity worldwide.
- Burden is disproportionately higher in low- and middle-income countries (LMICs), where access to supportive care is limited. Most research data, however, come from high-income countries (a limitation noted in the 2024 Heemskerk systematic review).
- In the US 2024-2025 season, RSV was associated with an estimated 3.6-6.5 million outpatient visits and 190,000-350,000 hospitalisations across all ages (CDC MMWR, 2025).
8. Recent Development - RSV Prevention
A significant epidemiological shift is underway following the introduction of:
- Nirsevimab (Beyfortus) - a long-acting monoclonal antibody approved by the FDA in July 2023 for infants entering their first and second RSV season. CDC data show it has reduced RSV hospitalisation rates in infants aged 0-7 months by 28-43% compared to pre-immunisation seasons (MMWR, 2025).
- Maternal RSV vaccine (Abrysvo) - for administration in pregnancy to protect neonates passively.
These interventions are expected to meaningfully change the epidemiological landscape in coming years.
Sources: NICE NG9; CPS Bronchiolitis Statement; AAFP 2023 Evidence Review; Heemskerk et al. (PMID 39098881); CDC MMWR RSV 2024-25; Swanson's Family Medicine Review, p. 583; Red Book 2021; Cummings Otolaryngology, p. 3804.
This is a shared conversation. Sign in to Orris to start your own chat.